

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 02-1239-A)
(Formerly Attorney Docket No. TRVZ 20014P)

In re Application of:)	
)	
Karl Tryggvason, et al.)	
)	Group Art Unit: 1645
Serial No.: 09/756,071)	
)	Examiner: Hines, Jana A.
Filed: January 8, 2001)	
)	
For: Laminin Chains: Diagnostic Uses)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop: IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

McDonnell, Boehnen, Hulbert & Berghoff
300 S. Wacker Drive, Suite 3200
Chicago, IL 60606
312-913-0001

11/13/2003 SSESHE1 00000052 132490 09756071
01 FC:1806 180.00 DA

FEES

- ☐ No fee is owed by the applicant(s).
☒ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.
☐ The **Petition Fee of \$130.00** set forth in 37 C.F.R. § 1.17(i) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☐ Attached is a check in the amount of \$180.00.
☒ Charge Deposit Account No. 13-2490 in the amount of \$180.00. (A duplicate copy of this communication is enclosed for that purpose.)


Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490. A duplicate copy of this communication is enclosed for this purpose.

CERTIFICATE OF MAILING AS "EXPRESS MAIL" (37 CFR 1.10) I hereby certify that this correspondence and all attached paper(s) or fee(s) is being deposited with sufficient postage, with the United States Postal Service as EXPRESS MAIL POST OFFICE TO ADDRESSEE in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, CA 22313-1450, with sufficient postage, on this 7th Day of November, 2003. under Express Mail Certificate No. EV333556908US.

Date: _____

11/7/03

Respectfully submitted,



David S. Harper
Registration No. 42,636

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

McDonnell, Boehnen, Hulbert & Berghoff
300 S. Wacker Drive, Suite 3200
Chicago, IL 60606
312-913-0001

U.S. Patent Documents:

1. Jonathan C.R. Jones, et al., U.S. Patent No. 6,294,356, Issued on September 25, 2001.

Foreign Documents:

2. Jones, et al., PCT Published Application No. WO 00/26342, Published on May 11, 2000.
3. Desmos, Inc., et al., PCT Published Application No. WO 00/34441, Published on June 15, 2000.
4. Findell, et al., PCT Published Application No. WO 01/87239, Published on November 22, 2001.

Other Documents:

5. Aberdam et al., (1994), Nature Genetics, "Herlitz's junctional epidermolysis bullosa is linked to mutations in the gene (LAMC2) for the $\gamma 2$ subunit of nicein/kalinin (LAMININ-5)", Vol: 6: pp. 299-304.
6. Amano, et al., (2000), The Journal of Biological Chemistry, "Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5 $\gamma 2$ chain", Vol: 275(30), pp. 22728-22735.
7. Anderson, et al., (2001), The Laryngoscope, "Tumor deposition of laminin-5 and the relationship with perineural invasion", Vol: 111, pp. 2140-2143.
8. Calaluce, et al., (2001), Molecular Carcinogenesis, "Laminin-5-mediated gene expression in human prostate carcinoma cells", Vol: 30, pp. 119-129.
9. Davis, et al., (2001), The Prostate, "Unique expression pattern of the $\alpha 6 \beta 4$ integrin and Laminin-5 in human prostate carcinoma", Vol: 46, pp. 240-248.
10. Engvall, et al., (1990), Cell Regulation, "Distribution and isolation of four laminin variants; tissue restricted distribution of heterotrimers assembled from five different subunits", Vol: 1, pp. 731-740.
11. Fukushima, et al., (2001), Mod. Pathol., "Expression of laminin-5- γ -2 chain in intraductal papillary-mucinous and invasive ductal tumors of the pancreas", Vol: 14(5), pp. 404-409.

12. Gianelli, et al., (1997), Science, "Induction of Cell Migration by Matrix Metalloprotease-2 Cleavage of Laminin-5", Vol: 277, pp. 225-228.
13. Gianelli and Antonaci, (2001), Clinical and Experimental Metastasis, "Biological and Clinical Relevance of Laminin-5 in Cancer", Vol: 18, pp. 439-443.
14. Goldfinger, et al., (1998), J. Cell Biol., "Processing of Laminin-5 and its functional consequences: Role of Plasmin and Tissue-type Plasminogen Activator", Vol: 141, pp. 255-265.
15. Gonzales, et al., (1999), Mol. Biol. of the Cell, "A cell signal pathway involving laminin-5, $\alpha 3 \beta 1$ integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation", Vol: 10, pp. 259-270.
16. Grassi, et al., (1999), Journal of Cell Science, "The SFL activity secreted by metastatic carcinoma cells is related to laminin 5 and mediates cell scattering in an integrin-independent manner", Vol: 112, pp. 2511-2520.
17. Haas, et al., (2001), The Journal of Histochemistry & Cytochemistry, "A comparative quantitative analysis of laminin-5 in the basement membrane of normal, hyperplastic, and malignant oral mucosa by confocal immunofluorescence imaging", Vol: 49(10), pp. 1261-1268.
18. Habermann, et al., (2001), Scand J. Gastroenterol, "Ulcerative colitis and colorectal carcinoma", Vol: 7, pp. 751-758.
19. Hao, et al., (1996), American Journal of Pathology, "Differential expression of laminin 5 ($\alpha 3 \beta 3 \gamma 2$) by human malignant and normal prostate", Vol: 149(4), pp. 1341-1349.
20. Heagerty, et al., (1986), Lancet, "GB3 monoclonal antibody for diagnosis of junctional epidermolysis bullosa", Vol: 860, page 8485.
21. Heagerty, et al., (1987), British J. Dermatol, "Raid prenatal diagnosis of epidermolysis bullosa letalis using GB3 monoclonal antibody", Vol: 17, pp. 271-275.
22. Hellman, et al., (2000), Int. J. Gynecol. Cancer., "Cancer of the vagina: Laminin-5 $\gamma 2$ chain expression and prognosis", Vol: 10, pp. 391-396.
23. Henning, et al., (1999), Histopathology, "Loss of laminin-5 in the epithelium-stroma interface: an immunohistochemical marker of malignancy in epithelial lesions of the breast", Vol: 34, pp. 305-309.

24. Hlubek, et al., (2001), Cancer Research, "Expression of the invasion factor laminin γ 2 in colorectal carcinomas is regulated by β -catenin¹", Vol: 61, pp. 8089-8093.
25. Hsi, et al., (1986), J. Reprod. Immunology, "Monoclonal antibodies to human amnion", Vol: 9, pp. 11-21.
26. Kagesato, et al., (2001), Japan J. Cancer Research, "Sole expression of laminin γ 2 chain in invading tumor cells and its association with stromal fibrosis in lung adenocarcinomas", Vol: 21, pp. 184-192.
27. Katoh, et al., (2002), Oncology, "Correlation between laminin-5 γ 2 chain expression and epidermal growth factor receptor expression and its clinicopathological significance in squamous cell carcinoma of the tongue, Vol: 62, pp. 318-326.
28. Kallunki, et al., (1992), J. Cell Biol., "A truncated laminin chain homologous to the B2 chain: Structure, spatial expression, and chromosomal assignment", Vol: 118, pp. 679-693.
29. Koshikawa, et al., (1999), Cancer Research, "Overexpression of laminin γ 2 chain monomer in invading gastric carcinoma cells, Vol: 59, pp. 5596-5601.0
30. Lenander, et al., (2001), Analytical Cellular Pathology, "Laminin-5 γ 2 chain expression correlates with unfavorable prognosis in colon carcinomas", Vol: 22, pp. 201-209.
31. Lohi, et al., (2000), APMIS, "Basement membrane laminin-5 is deposited in colorectal adenomas and carcinomas and serves as a ligand for α 3 β 1 integrin", Vol: 108, pp. 161-172.
32. Lugassy, et al., (1999), J. Cutaneous Pathol., "Tumor microvessels in melanoma express the beta-2 chain of laminin. Implications for melanoma metastasis", Vol: 26, pp. 222-226.
33. Määttä, et al., (2001), The Journal of Histochemistry & Cytochemistry, "Comparative analysis of the distribution of laminin chains in the basement membranes in some malignant epithelial tumors: The α 1 chain of laminin shows a selected expression pattern in human carcinomas", Vol: 49(6), pp. 711-725.
34. Määttä, et al., (1999), Journal of Pathology, "Expression of the laminin γ 2 chain in different histological types of lung carcinoma. A study by immunohistochemistry and *in situ* hybridization", Vol: 188, pp. 361-368.

35. Manda, et al., (2000), Biochemical and Biophysical Research Communications, "Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas", Vol: 275, pp. 440-445.
36. Marinkovich, et al., (1992), JBC, "The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor", Vol: 267, pp. 17900-17906.
37. Martin, et al., (1998), Mol. Med., "Down-regulation of laminin-5 in breast carcinoma cells", Vol: 4(9), pp. 602-613.
38. Matsui, et al., (1995), J. Invest. Dermatology, " γ 2 chain of Laminin-5 is recognized by Monoclonal Antibody GB3", Vol: 105, pp. 648-652.
39. Matsui, et al., (1995), JBC, "The Assembly of Laminin-5 Subunits", Vol: 270(40), pp. 23496-23503.
40. McMillan, et al., (1997), Br. J. Dermatol., "Immunohistochemical analysis of the skin in junctional epidermolysis bullosa using laminin 5 chain specific antibodies is of limited value in predicting the underlying gene mutation", Vol: 136, pp. 817-822.
41. Mizushima, et al., (1998), Horm. Res., "Wide Distribution of Laminin-5 γ chain in basement membranes of various human tissues", Vol: 50 (Suppl. 2), pp. 7-14.
42. Mizushima, et al., (1996), J. Biochem., "Differential expression of laminin-5/ladsin subunits in human tissues and cancer cell lines and their induction by tumor promoter and growth factors", Vol: 120, pp. 1196-1202.
43. Moriya, et al., (2001), Cancer, "Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size", Vol: 19(6), pp. 1129-1141.
44. Niki, et al., (2002), American Journal of Pathology, "Frequent co-localization of cox-2 and laminin-5 γ 2 chain at the invasive front of early-stage lung adenocarcinomas", Vol: 160(3), pp. 1129-1130.
45. Nordemar, et al., (2001), Anticancer Research, "Laminin-5 as a predictor of invasiveness in cancer *in situ* lesions of the larynx", Vol: 21, pp. 509-512.
46. Nordstrom, et al., (2002), Int. J. Gynecol., "Laminin-5 γ 2 chain as an invasivity marker for uni-and multifocal lesions in the lower anogenital tract", Vol: 12, pp. 105-109.


47. Ono, et al., (2002), Cancer Letters, "Epidermal growth factor receptor gene amplification is correlated with laminin-5 γ 2 chain expression in oral squamous cell carcinoma cell lines", Vol: 175, pp. 197-204.
48. Patarroyo, et al., (2002), Cancer Biology, "Laminin isoforms in tumor invasion, angiogenesis and metastasis", Vol: 12, pp. 197-207.
49. Patel, et al., (2002), Int. J. Cancer, "Laminin- γ 2 overexpression in head-and-neck squamous cell carcinoma", Vol: 99, pp. 583-588.
50. Pyke, et al., (1994), American Journal, "The γ 2 chain of laminin/laminin 5 is preferentially expressed in invading malignant cells in human cancers", Vol: 145(4), pp. 782-791.
51. Pyke, et al., (1995), Cancer research, "Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas", Vol: 55(18), pp. 4132-4139.
52. Rouselle, et al., (1991), J. Cell Biol., "Kalinin: an epithelium-specific basement membrane adhesion molecule that is a component of anchoring filaments", Vol: 114(3), pp. 567-576.
53. Rouselle, et al., (1994), J. Cell Biol., "Kalinin is more efficient than laminin in promoting adhesion of primary keratinocytes and some other epithelial cells and has a different requirement of integrin receptors", Vol: 125, pp. 205-214.
54. Salo, et al., (1999), Matrix Biol., "Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the γ 2 chain gene (LAMC2) with activity in transgenic mice", Vol: 18, pp. 197-210.
55. Salo, et al., (1999), Acta Univ. Oul.D 540, "Laminin-5: Function of the γ 2 chain in epithelial cell adhesion and migration, and expression in epithelial cells and carcinomas" Doctoral Dissertation.
56. Seftor, et al., (2001), Cancer Research, "Cooperative interactions of laminin 5 γ 2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma", Vol: 61, pp. 6322-6327.
57. Skyldberg, et al., (1999), Journal of the National Cancer Institute, "Laminin-5 as a marker of invasiveness in cervical lesions", Vol: 91(21), pp. 1882-1887.

58. Soini, et al., (1996), Journal of Pathology, "Expression of the laminin γ 2 chain in pancreatic adenocarcinoma", Vol: 180, pp. 290-294.
59. Sordat, et al., (1998), J. Pathol., "Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia", Vol: 185, pp. 44-52.
60. Sordat, et al., (2000), Int. J. Cancer., "Tumor cell budding and Laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment", Vol: 88, pp. 708-717.
61. Takahashi, et al., (2002), Cancer, Cytoplasmic Expression of Laminin γ 2 Chain Correlates with Postoperative Hepatic Metastasis and Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma", Vol: 94(6), pp. 1894-1901.
62. Tani, et al., (1997), American Journal of Pathology, "Pancreatic carcinomas deposit laminin-5 preferably adhere to laminin-5, and migrate on the newly deposited basement membrane", Vol: 151(5), pp. 1289-1302.
63. Tsuji, et al., (2002), Clinical & Experimental Metastasis, "Regulation of melanoma cell migration and invasion by laminin-5 and α 3 β 1 integrin (VLA-3), Vol: 19, pp. 127-134.
64. Tunggal, et al., (2002), American Journal of Pathology, "Defective laminin 5 processing in cylindroma cells", Vol: 160(2), pp. 459-468.
65. Vailly, et al., (1994), Eur. J. Biochem., "The 100-kDa chain of nicein/kalinin is a laminin B2 chain variant", Vol: 219, pp. 209-218.
66. Verrando, et al., (1987), Exp. Cell Res., "Monoclonal antibody GB3, a new probe for the study of human basement membranes and hemidesmosomes", Vol: 170, page 116-128.
67. Verrando, et al, (1991), Lab. Investigation, "Monoclonal antibody GB3 defines a widespread defect of several basement membranes and a keratinocyte dysfunction in patients with lethal junctional 4perdermolysis bullosa", Vol: 64, pp. 85-92.
68. Yamamoto, et al., (2001), Clinical Cancer Research, "Expression of the γ 2 chain of Laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma", Vol: 7, pp. 896-900.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Date: 11/7/03

Respectfully Submitted,

By: 
David S. Harper
Reg. No. 42,636

McDonnell, Boehnen, Hulbert & Berghoff
300 S. Wacker Drive, Suite 3200
Chicago, IL 60606
312-913-0001

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

02-1239-A
(Formerly Atty Docket
No. TRVZ 20014P)

Serial No.

09/756,071

Applicant:

Name Karl Tryggvason

Filing Date:

January 8, 2001

Group:

1645

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	6,294,356	9/25/01	Jones, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	2.	WO 00/26342	5/11/00	PCT			x	
	3.	WO 00/34441	6/15/00	PCT			x	
	4.	WO 01/87239	11/22/01	PCT			x	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

5.	Aberdam et al., (1994), Nature Genetics, "Herlitz's junctional epidermolysis bullosa is linked to mutations in the gene (LAMC2) for the $\gamma 2$ subunit of nicein/kalinin (LAMININ-5)", Vol: 6: pp. 299-304.
6.	Amano, et al., (2000), The Journal of Biological Chemistry, "Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5 $\gamma 2$ chain", Vol: 275(30), pp. 22728-22735.
7.	Anderson, et al., (2001), The Laryngoscope, "Tumor deposition of laminin-5 and the relationship with perineural invasion", Vol: 111, pp. 2140-2143.
8.	Calaluze, et al., (2001), Molecular Carcinogenesis, "Laminin-5-mediated gene expression in human prostate carcinoma cells", Vol: 30, pp. 119-129.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

02-1239-A
(Formerly Atty Docket
No. TRVZ 20014P)

Serial No.

09/756,071

Applicant:

Name Karl Tryggvason

Filing Date:

January 8, 2001

Group:

1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

9.	Davis, et al., (2001), The Prostate, "Unique expression pattern of the $\alpha 6 \beta 4$ integrin and Laminin-5 in human prostate carcinoma", Vol: 46, pp. 240-248.
10.	Engvall, et al., (1990), Cell Regulation, "Distribution and isolation of four laminin variants; tissue restricted distribution of heterotrimers assembled from five different subunits", Vol: 1, pp. 731-740.
11.	Fukushima, et al., (2001), Mod. Pathol., "Expression of laminin-5- γ -2 chain in intraductal papillary-mucinous and invasive ductal tumors of the pancreas", Vol: 14(5), pp. 404-409.
12.	Gianelli, et al., (1997), Science, "Induction of Cell Migration by Matrix Metalloprotease-2 Cleavage of Laminin-5", Vol: 277, pp. 225-228.
13.	Gianelli and Antonaci, (2001), Clinical and Experimental Metastasis, "Biological and Clinical Relevance of Laminin-5 in Cancer", Vol: 18, pp. 439-443.
14.	Goldfinger, et al., (1998), J. Cell Biol., "Processing of Laminin-5 and its functional consequences: Role of Plasmin and Tissue-type Plasminogen Activator", Vol: 141, pp. 255-265.
15.	Gonzales, et al., (1999), Mol. Biol. of the Cell, "A cell signal pathway involving laminin-5, $\alpha 3 \beta 1$ integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation", Vol: 10, pp. 259-270.
16.	Grassi, et al., (1999), Journal of Cell Science, "The SFL activity secreted by metastatic carcinoma cells is related to laminin 5 and mediates cell scattering in an integrin-independent manner", Vol: 112, pp. 2511-2520.
17.	Haas, et al., (2001), The Journal of Histochemistry & Cytochemistry, "A comparative quantitative analysis of laminin-5 in the basement membrane of normal, hyperplastic, and malignant oral mucosa by confocal immunofluorescence imaging", Vol: 49(10), pp. 1261-1268.
18.	Habermann, et al., (2001), Scand J. Gastroenterol, "Ulcerative colitis and colorectal carcinoma", Vol: 7, pp. 751-758.
19.	Hao, et al., (1996), American Journal of Pathology, "Differential expression of laminin 5 ($\alpha 3 \beta 3 \gamma 2$) by human malignant and normal prostate", Vol: 149(4), pp. 1341-1349.
20.	Heagerty, et al., (1986), Lancet, "GB3 monoclonal antibody for diagnosis of junctional epidermolysis bullosa", Vol: 860, page 8485.
21.	Heagerty, et al., (1987), British J. Dermatol, "Rapid prenatal diagnosis of epidermolysis bullosa letalis using GB3 monoclonal antibody", Vol: 17, pp. 271-275.
22.	Hellman, et al., (2000), Int. J. Gynecol. Cancer, "Cancer of the vagina: Laminin-5 γ 2 chain expression and prognosis", Vol: 10, pp. 391-396.
23.	Henning, et al., (1999), Histopathology, "Loss of laminin-5 in the epithelium-stroma interface: an immunohistochemical marker of malignancy in epithelial lesions of the breast", Vol: 34, pp. 305-309.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

02-1239-A
(Formerly Atty Docket
No. TRVZ 20014P)

Serial No.

09/756,071

Applicant:

Name Karl Tryggvason

Filing Date:

January 8, 2001

Group:

1645

24.	Hlubek, et al., (2001), Cancer Research, "Expression of the invasion factor laminin γ 2 in colorectal carcinomas is regulated by β -catenin ¹ ", Vol: 61, pp. 8089-8093.
25.	Hsi, et al., (1986), J. Reprod. Immunology, "Monoclonal antibodies to human amnion", Vol: 9, pp. 11-21.
26.	Kagesato, et al., (2001), Japan J. Cancer Research, "Sole expression of laminin γ 2 chain in invading tumor cells and its association with stromal fibrosis in lung adenocarcinomas", Vol: 21, pp. 184-192.
27.	Katoh, et al., (2002), Oncology, "Correlation between laminin-5 γ 2 chain expression and epidermal growth factor receptor expression and its clinicopathological significance in squamous cell carcinoma of the tongue", Vol: 62, pp. 318-326.
28.	Kallunki, et al., (1992), J. Cell Biol., "A truncated laminin chain homologous to the B2 chain: Structure, spatial expression, and chromosomal assignment", Vol: 118, pp. 679-693.
29.	Koshikawa, et al., (1999), Cancer Research, "Overexpression of laminin γ 2 chain monomer in invading gastric carcinoma cells", Vol: 59, pp. 5596-5601.
30.	Lenander, et al., (2001), Analytical Cellular Pathology, "Laminin-5 γ 2 chain expression correlates with unfavorable prognosis in colon carcinomas", Vol: 22, pp. 201-209.
31.	Lohi, et al., (2000), APMIS, "Basement membrane laminin-5 is deposited in colorectal adenomas and carcinomas and serves as a ligand for α 3 β 1 integrin", Vol: 108, pp. 161-172.
32.	Lugassy, et al., (1999), J. Cutaneous Pathol., "Tumor microvessels in melanoma express the beta-2 chain of laminin. Implications for melanoma metastasis", Vol: 26, pp. 222-226.
33.	Määttä, et al., (2001), The Journal of Histochemistry & Cytochemistry, "Comparative analysis of the distribution of laminin chains in the basement membranes in some malignant epithelial tumors: The α 1 chain of laminin shows a selected expression pattern in human carcinomas", Vol: 49(6), pp. 711-725.
34.	Määttä, et al., (1999), Journal of Pathology, "Expression of the laminin γ 2 chain in different histological types of lung carcinoma. A study by immunohistochemistry and <i>in situ</i> hybridization", Vol: 188, pp. 361-368.
35.	Manda, et al., (2000), Biochemical and Biophysical Research Communications, "Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas", Vol: 275, pp. 440-445.
36.	Marinkovich, et al., (1992), JBC, "The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor", Vol: 267, pp. 17900-17906.
37.	Martin, et al., (1998), Mol. Med., "Down-regulation of laminin-5 in breast carcinoma cells", Vol: 4(9), pp. 602-613.
38.	Matsui, et al., (1995), J. Invest. Dermatology, " γ 2 chain of Laminin-5 is recognized by Monoclonal Antibody GB3", Vol: 105, pp. 648-652.
39.	Matsui, et al., (1995), JBC, "The Assembly of Laminin-5 Subunits", Vol: 270(40), pp. 23496-23503.
40.	McMillan, et al., (1997), Br. J. Dermatol., "Immunohistochemical analysis of the skin in junctional epidermolysis bullosa using laminin 5 chain specific antibodies is of limited value in predicting the underlying gene mutation", Vol: 136, pp. 817-822.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.

02-1239-A
(Formerly Atty Docket
No. TRVZ 20014P)

Serial No.

09/756,071

Applicant:

Name Karl Tryggvason

Filing Date:

January 8, 2001

Group:

1645

41.	Mizushima, et al., (1998), Horm. Res., "Wide Distribution of Laminin-5 γ chain in basement membranes of various human tissues", Vol: 50 (Suppl. 2), pp. 7-14.
42.	Mizushima, et al., (1996), J. Biochem., "Differential expression of laminin-5/ladsin subunits in human tissues and cancer cell lines and their induction by tumor promoter and growth factors", Vol: 120, pp. 1196-1202.
43.	Moriya, et al., (2001), Cancer, "Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size", Vol: 19(6), pp. 1129-1141.
44.	Niki, et al., (2002), American Journal of Pathology, "Frequent co-localization of cox-2 and laminin-5 γ 2 chain at the invasive front of early-stage lung adenocarcinomas", Vol: 160(3), pp. 1129-1130.
45.	Nordemar, et al., (2001), Anticancer Research, "Laminin-5 as a predictor of invasiveness in cancer <i>in situ</i> lesions of the larynx", Vol: 21, pp. 509-512.
46.	Nordstrom, et al., (2002), Int. J. Gynecol., "Laminin-5 γ 2 chain as an invasivity marker for uni-and multifocal lesions in the lower anogenital tract", Vol: 12, pp. 105-109.
47.	Ono, et al., (2002), Cancer Letters, "Epidermal growth factor receptor gene amplification is correlated with laminin-5 γ 2 chain expression in oral squamous cell carcinoma cell lines", Vol: 175, pp. 197-204.
48.	Patarroyo, et al., (2002), Cancer Biology, "Laminin isoforms in tumor invasion, angiogenesis and metastasis", Vol: 12, pp. 197-207.
49.	Patel, et al., (2002), Int. J. Cancer, "Laminin- γ 2 overexpression in head-and-neck squamous cell carcinoma", Vol: 99, pp. 583-588.
50.	Pyke, et al., (1994), American Journal, "The γ 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers", Vol: 145(4), pp. 782-791.
51.	Pyke, et al., (1995), Cancer research, "Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas", Vol: 55(18), pp. 4132-4139.
52.	Rouselle, et al., (1991), J. Cell Biol., "Kalinin: an epithelium-specific basement membrane adhesion molecule that is a component of anchoring filaments", Vol: 114(3), pp. 567-576.
53.	Rouselle, et al., (1994), J. Cell Biol., "Kalinin is more efficient than laminin in promoting adhesion of primary keratinocytes and some other epithelial cells and has a different requirement of integrin receptors", Vol: 125, pp. 205-214.
54.	Salo, et al., (1999), Matrix Biol., "Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the γ 2 chain gene (LAMC2) with activity in transgenic mice", Vol: 18, pp. 197-210.
55.	Salo, et al., (1999), Acta Univ. Oul.D 540, "Laminin-5: Function of the γ 2 chain in epithelial cell adhesion and migration, and expression in epithelial cells and carcinomas" Doctoral Dissertation.
56.	Seftor, et al., (2001), Cancer Research, "Cooperative interactions of laminin 5 γ 2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma", Vol: 61, pp. 6322-6327.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. # 02-1239-A (Formerly Atty Docket No. TRVZ 20014P)	Serial No. # 09/756,071
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		Name Karl Tryggvason	
		Filing Date:	Group:
		# January 8, 2001	# 1645

57.	Skyldberg, et al., (1999), Journal of the National Cancer Institute, "Laminin-5 as a marker of invasiveness in cervical lesions", Vol: 91(21), pp. 1882-1887.
58.	Soini, et al., (1996), Journal of Pathology, "Expression of the laminin γ 2 chain in pancreatic adenocarcinoma", Vol: 180, pp. 290-294.
59.	Sordat, et al., (1998), J. Pathol., "Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia", Vol: 185, pp. 44-52.
60.	Sordat, et al., (2000), Int. J. Cancer., "Tumor cell budding and Laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment", Vol: 88, pp. 708-717.
61.	Takahashi, et al., (2002), Cancer, Cytoplasmic Expression of Laminin γ 2 Chain Correlates with Postoperative Hepatic Metastasis and Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma", Vol: 94(6), pp. 1894-1901.
62.	Tani, et al., (1997), American Journal of Pathology, "Pancreatic carcinomas deposit laminin-5 preferably adhere to laminin-5, and migrate on the newly deposited basement membrane", Vol: 151(5), pp. 1289-1302.
63.	Tsuji, et al., (2002), Clinical & Experimental Metastasis, "Regulation of melanoma cell migration and invasion by laminin-5 and α 3 β 1 integrin (VLA-3)", Vol: 19, pp. 127-134.
64.	Tunggal, et al., (2002), American Journal of Pathology, "Defective laminin 5 processing in cylindroma cells", Vol: 160(2), pp. 459-468.
65.	Vailly, et al., (1994), Eur. J. Biochem., "The 100-kDa chain of nicein/kalinin is a laminin B2 chain variant", Vol: 219, pp. 209-218.
66.	Verrando, et al., (1987), Exp. Cell Res., "Monoclonal antibody GB3, a new probe for the study of human basement membranes and hemidesmosomes", Vol: 170, page 116-128.
67.	Verrando, et al, (1991), Lab. Investigation, "Monoclonal antibody GB3 defines a widespread defect of several basement membranes and a keratinocyte dysfunction in patients with lethal junctional 4perdermolysis bullosa", Vol: 64, pp. 85-92.
68.	Yamamoto, et al., (2001), Clinical Cancer Research, "Expression of the γ 2 chain of Laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma", Vol: 7, pp. 896-900.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.